DarioHealth Corp.
DarioHealth Corp. (DRIO) Financial Performance & Income Statement Overview
Explore the financials of DarioHealth Corp. (DRIO), including yearly and quarterly data on income, cash flow, and balance sheets.
DarioHealth Corp. (DRIO) Income Statement & Financial Overview
Explore comprehensive income reports for DarioHealth Corp. DRIO, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $7.60M | $7.42M | $6.25M | $5.76M |
| Cost of Revenue | $3.40M | $3.55M | $3.50M | $3.33M |
| Gross Profit | $4.20M | $3.88M | $2.76M | $2.43M |
| Gross Profit Ratio | $0.55 | $0.52 | $0.44 | $0.42 |
| R&D Expenses | $5.28M | $5.45M | $6.81M | $6.64M |
| SG&A Expenses | $10.59M | $10.46M | $12.02M | $13.05M |
| Operating Expenses | $108.02M | -$8.15M | $18.83M | $19.69M |
| Total Costs & Expenses | $111.42M | -$4.61M | $22.33M | $23.02M |
| Interest Income | $161000.00 | $0.00 | $0.00 | $390000.00 |
| Interest Expense | -$3.26M | $0.00 | $0.00 | $920000.00 |
| Depreciation & Amortization | $2.13M | $2.13M | $1.84M | $1.48M |
| EBITDA | -$9.53M | -$9.90M | -$14.35M | -$16.53M |
| EBITDA Ratio | -$1.25 | -$1.33 | -$2.29 | -$2.87 |
| Operating Income | -$103.82M | -$12.03M | -$16.07M | -$17.26M |
| Operating Income Ratio | -$13.65 | -$1.62 | -$2.57 | -$3.00 |
| Other Income/Expenses (Net) | $94.34M | $26.64M | $2.58M | $8.09M |
| Income Before Tax | -$9.48M | $14.61M | -$13.61M | -$9.17M |
| Income Before Tax Ratio | -$1.25 | $1.97 | -$2.18 | -$1.59 |
| Income Tax Expense | $155000.00 | -$13000.00 | -$10.24M | -$1.99M |
| Net Income | -$9.63M | -$12.33M | -$3.37M | -$6.92M |
| Net Income Ratio | -$1.27 | -$1.66 | -$0.54 | -$1.20 |
| EPS | $0.36 | $0.36 | -$0.08 | -$0.20 |
| Diluted EPS | $0.36 | $0.36 | -$0.08 | -$0.20 |
| Weighted Avg Shares Outstanding | $40.42M | $40.42M | $39.83M | $34.44M |
| Weighted Avg Shares Outstanding (Diluted) | $40.42M | $40.42M | $39.83M | $34.44M |
The company's financials show resilient growth, with revenue advancing from $5.76M in Q1 2024 to $7.60M in Q4 2024. Gross profit remained healthy with margins at 55% in Q4 2024 compared to 42% in Q1 2024. Operating income hit -$103.82M last quarter, sustaining a consistent -1365% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$9.53M. Net income rose to -$9.63M, while earnings per share reached $0.36. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan